The discipline of Clinical Pharmacology seeks to apply an understanding of the fundamental mechanisms of drug action to improve the therapy of human diseases. The Division of Clinical Pharmacology at Vanderbilt offers an outstanding research-based fellowship program committed to training future leaders in the discipline. The mentoring faculty for this postdoctoral training program are 17 faculty members in the Division of Clinical Pharmacology, along with 27 selected faculty members in other departments. Collaborations among investigators focusing on common research themes are well-established in the Division;areas of research focus include 1) Drug metabolism/Pharmacogenetics and pharmacogenomics;2) Eicosanoid and lipid mediator pharmacology;3) Vascular biology and control of the circulation;4) Ion channel pharmacology and arrhythmia pharmacogenomics;5) Bone and cancer pharmacology;and 6) Pharmacoepidemiology. Additional collaborative efforts exist in pediatrics, cancer pharmacology and neuropharmacology, among others. The primary activity of trainees is research training in a mentored setting on questions directly relevant to drug action in man. Research can vary from bench-based to clinical studies. There are currently 30 postdoctoral fellows in the program and seven are supported by this grant. The duration of training is 2-3 years and individuals holding either an M.D., Ph.D., or Pharm.D. degree are supported. Research training under the direction of individual faculty mentors is supplemented by didactic course work and seminars. Required courses of trainees include research ethics, responsible conduct of research, biostatistics and study design, drug regulation and development, and pharmacokinetics/pharmacodynamics. In addition, attendance at Clinical Pharmacology Grand Rounds and a weekly Fellows'Lecture Series is required. This curriculum supplements the trainees'research experience and provides a broad knowledge base that will allow for fellows to develop into successful leaders in Clinical Pharmacology. Recent commitments by Vanderbilt to grow Clinical Pharmacology offer a unique opportunity to further enhance the training program. These include the opening of the Oates Institute of Experimental Therapeutics and the establishment of the Vanderbilt Center for Bone Biology - both components of the Division of Clinical Pharmacology. The overall mission of the Vanderbilt Clinical Pharmacology training program is to train investigators who will ultimately assume leadership positions in the discipline. Of trainees supported by the award in the past 10 years approximately 90% are in academic medicine, industry or government. Clinical Pharmacology at Vanderbilt is a vibrant and dynamic enterprise poised for significant growth. The excellence of the training program has resulted in substantially more applicants than positions, therefore support for an additional training position per year is requested in this renewal.

Public Health Relevance

There is a large and growing shortage of individuals with expertise in clinical pharmacology: the science of human drug response. The Clinical Pharmacology T32 fellowship training program at Vanderbilt was established in 1977 and provides outstanding training and research opportunities in clinical pharmacology to talented individuals. We seek continued support for our highly successful efforts to train young investigators in the science of clinical pharmacology.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Special Emphasis Panel (ZGM1-BRT-5 (PD))
Program Officer
Okita, Richard T
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Sidorova, Tatiana N; Yermalitskaya, Liudmila V; Mace, Lisa C et al. (2015) Reactive ?-ketoaldehydes promote protein misfolding and preamyloid oligomer formation in rapidly-activated atrial cells. J Mol Cell Cardiol 79:295-302
Sidorova, Tatiana N; Mace, Lisa C; Wells, K Sam et al. (2014) Hypertension is associated with preamyloid oligomers in human atrium: a missing link in atrial pathophysiology? J Am Heart Assoc 3:e001384
Yang, Tao; Chun, Young Wook; Stroud, Dina M et al. (2014) Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current. Circulation 130:224-34
Figueroa, RocĂ­o A; Arnold, Amy C; Nwazue, Victor C et al. (2014) Acute volume loading and exercise capacity in postural tachycardia syndrome. J Appl Physiol (1985) 117:663-8
Kirabo, Annet; Fontana, Vanessa; de Faria, Ana P C et al. (2014) DC isoketal-modified proteins activate T cells and promote hypertension. J Clin Invest 124:4642-56
Trott, Daniel W; Thabet, Salim R; Kirabo, Annet et al. (2014) Oligoclonal CD8+ T cells play a critical role in the development of hypertension. Hypertension 64:1108-15
Okamoto, Luis E; Gamboa, Alfredo; Shibao, Cyndya A et al. (2014) Nebivolol, but not metoprolol, lowers blood pressure in nitric oxide-sensitive human hypertension. Hypertension 64:1241-7
Bowton, Erica; Field, Julie R; Wang, Sunny et al. (2014) Biobanks and electronic medical records: enabling cost-effective research. Sci Transl Med 6:234cm3
Van Driest, S L; Shi, Y; Bowton, E A et al. (2014) Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther 95:423-31
Sosa, I R; Ellery, P; Mast, A et al. (2014) Acquired factor V deficiency in a patient without evidence of a classical inhibitor. Haemophilia 20:e81-3

Showing the most recent 10 out of 107 publications